List view / Grid view
While high costs are hindering growth in the lab automation market, research highlights that new innovations like AI offer potential to expand this rapidly evolving industry.
The $10 billion acquisition involves advancement of a novel inhaled therapy which has potential to redefine standard of care in respiratory disease.
Cell therapy expert Lindsay Davies, PhD, FHEA, discusses the key considerations for moving the needle to broader adoption of CGTs in Europe.
The deal between Gilead Sciences and Kymera Therapeutics could lead to development of safer and more effective cancer treatments.
The investment will support the company’s long-term vision for its future manufacturing capacity and medicine pipeline.
The UK Government’s £86 billion announcement will help strengthen innovation and economic growth in key sectors including life sciences.
The agreement involves an immunotherapy candidate with potential to innovate treatment of multiple tumour types, stated BMS.
The acquisition aligns with one of Sanofi’s four strategic disease areas and supports the company in utilising its immunology expertise to address areas of unmet need.
BioNTech’s commitment aligns with the UK Government’s Plan for Change, which involves accelerating growth of the pharmaceutical industry.
This article offers key industry perspectives on the UK government’s recent immigration whitepaper and highlights the challenge of balancing economic growth and attracting skilled talent.
As part of the agreement with Novo Nordisk, Lexicon Pharmaceuticals is eligible for total of $1 billion in upfront and potential milestone payments, alongside royalties.
The company’s new acquisition, valued up to $1 billion, supports development of in vivo cancer treatments and the future of cell therapy.
Investment in the new manufacturing plant strengthens Merck (MSD)’s vaccine production capacity in the US.
The proposed acquisition, worth nearly $300 million, could help to advance cell therapy in the oncology field.
Under growing global competition, this development highlights potential challenges for the UK to uphold large-scale pharmaceutical investments.
